Darryn Bampton

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

M. Brown, M. Millward, Yiping Yang, 2018, British Journal of Cancer.

721 Pixatimod (P) in combination with nivolumab (N) +/- low-dose cyclophosphamide (Cy) in advanced cancers: a phase IIA basket trial

Hong Wang, D. Davar, Amy Rose, 2022, Regular and Young Investigator Award Abstracts.

Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors

Yiping Yang, C. Cullinane, E. Hammond, 2018, Journal of Immunotherapy for Cancer.

PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.

J. Chien, M. Millward, B. Winterhoff, 2015, European journal of cancer.

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

M. Brown, M. Millward, Yiping Yang, 2018, British Journal of Cancer.

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors

N. Pavlakis, D. Goldstein, N. Waterhouse, 2023, Journal for ImmunoTherapy of Cancer.

An open-label, multi-center phase I study of the safety and tolerability of the novel immunomodulatory agent PG545 in subjects with advanced solid tumors.

M. Brown, M. Millward, Yiping Yang, 2017 .